Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 11/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128757 | 1.00 | BRAF (0.45) | BRAFMAPK3MAPK1CYP2D6CYP2C9 | |
| SCHEMBL4138112 | 0.93 | GRIN2B (0.46) | BRAFMAPK3MAPK1CYP2D6CYP2C9 | |
| SCHEMBL4138114 | 0.88 | BRAF (0.41) | BRAFMAPK3MAPK1CYP46A1 | |
| SCHEMBL4138109 | 0.88 | BRAF (0.41) | BRAFMAPK3MAPK1CYP46A1 | |
| SCHEMBL4133681 | 0.79 | BRAF (0.52) | BRAFMAPK3MAPK1 | |
| SCHEMBL4133680 | 0.79 | BRAF (0.52) | BRAFMAPK3MAPK1 | |
| SCHEMBL4133276 | 0.72 | BRAF (0.66) | BRAFMAPK3MAPK1 | |
| SCHEMBL4133266 | 0.69 | GRIN2B (0.56) | CYP2D6CYP2C9GRIN2B | |
| SCHEMBL4120599 | 0.69 | BRAF (0.70) | BRAFMAPK3MAPK1 | |
| SCHEMBL4120597 | 0.69 | BRAF (0.70) | BRAFMAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20060189627-A1 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189627-A1 | RAF inhibitor compounds and methods | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 55/4885MAPK1 57/4885 |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK3 55/4885MAPK1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.